Picropodophyllin

Drug Profile

Picropodophyllin

Alternative Names: AXL-1717

Latest Information Update: 08 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Axelar
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Astrocytoma
  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Jun 2015 Phase-II development is ongoing for Non-small cell lung cancer in Europe
  • 27 Dec 2013 Final efficacy and adverse events data from a phase II trial in Non-small cell lung cancer (late-stage disease; second-line therapy or greater) released by Axelar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top